Catalyst Wire Dossier Catalyst Wire Dossier

bioCSL Quadrivalent Influenza Vaccine

Quadrivalent influenza vaccine · Seqirus
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for bioCSL Quadrivalent Influenza Vaccine, covering 2016-02-23 to 2016-02-23. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above. [Phase 3]

See pricing